We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Subconjunctival bevacizumab for corneal neovascularization.
- Authors
Mesut Erdurmus; Yuksel Totan
- Abstract
Abstract Objective  To report the efficacy of subconjunctival bevacizumab injection in patients with corneal neovascularization (NV). Methods  This retrospective interventional case study included two eyes of two patients with corneal NV due to aqueous-deficient dry eye with filamentary keratitis in the first case, and corneal graft failure in the second case. Patients received a subconjunctival injection of 2.5 mg (0.1 ml) bevacizumab. Morphologic changes were investigated by slit-lamp biomicroscopy and corneal photography. Results  Corneal NV was dramatically regressed a week after injection in the first case. In the second case, minor vessels were regressed while the major one did not. No infection or inflammation was observed. No relapse was seen within the follow-up of two to three months. Conclusion  Subconjunctival injection of bevacizumab may offer an additional strategy for the treatment of corneal NV.
- Subjects
NEOVASCULARIZATION; BLOOD-vessel development; KERATITIS; INFLAMMATION
- Publication
Graefe's Archive of Clinical & Experimental Ophthalmology, 2007, Vol 245, Issue 10, p1577
- ISSN
0721-832X
- Publication type
Article
- DOI
10.1007/s00417-007-0587-4